REG - Adv Medical Solutns. - Half Year Trading Update

Advanced Medical SolutionsAnnouncement

06/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220706:nRSF4370Ra&default-theme=true

RNS Number : 4370R  Advanced Medical Solutions Grp PLC  06 July 2022

6 July 2022

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Half Year Trading Update

 

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, today announces its
unaudited trading update for the six months ended 30 June 2022 (the "Period").
The Group expects to announce its interim results on Wednesday 14(th)
September 2022.

 

The Group is pleased to report that trading in the first half of 2022
continues to be strong and in line with the Board's expectations as healthcare
markets return to normal. Group revenues for the period are expected to be
approximately £58 million. Both Business Units performed well during the
first half and the Board remains confident that the Group is on track to meet
market expectations for the full year.

 

Good progress continues to be made with key regulatory and clinical
programmes. In particular, the FDA 510(k) approval of LiquiBand(®) XL,
announced in May 2022, was a significant step in the development of the
LiquiBand(®) franchise and the product remains on track to be launched in the
US during Q3 this year.

 

Chris Meredith, Chief Executive Officer of AMS, commented: "I am delighted
with the ongoing strength in trading across the company and that we remain on
track to meet expectations this year. I am also very pleased with the progress
that our development teams have made. We continue to expect that a number of
key projects will reach major milestones over the next 12 months and will play
an important role in sustaining our top line growth in the long-term."

 

 

- End -

 

 

For further information, please contact:

 

 Advanced Medical Solutions Group plc                Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Consilium Strategic Communications                  Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal / Matthew Cole

 Investec Bank PLC (NOMAD & Broker)                  Tel: +44 (0) 20 7597 5970
 Daniel Adams / Gary Clarence

 HSBC Bank PLC (Broker)                              Tel: +44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made four acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products and AFS Medical, a specialist distributor of
minimally invasive surgical devices based in Austria.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has more than 700 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFFFLLDDIEIIF